A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

Trial Details

NCT ID
NCT06203210
Phase
PHASE3
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Ifinatamab deruxtecan
  • Topotecan
  • Amrubicin
  • Lurbinectedin
Locations (sample)
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Fullerton, California, United States|33.87029,-117.92534
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Participants must meet all the following criteria to be eligible for randomization into the study:
  • Sign and date the informed consent form (ICF) prior to the start of any study-specific qualification procedures.
  • Adults greater than or equal to (≥)18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.
  • Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →